2 minute read
A new scientific frontier
A NEW SCIENTIFIC FRONTIER IN PATIENT HEALTH
BARINDER BHULLAR
These are exciting times for cannabinoid researchers inspired by the purpose of using scientific knowledge to foster medical innovation. The cannabinoid drug market is bringing an exciting and expanded body of promising research to generate safe and effective therapies to benefit global patient health. The global sales of cannabinoid-based pharmaceuticals were US$798 million in 2020.
One fascinating area within the cannabinoid world is cannabidiol (CBD) research. The CBD-based pharmaceutical drug market is growing rapidly, powered by increasing scientific research indicating the positive therapeutic potential of CBD actives in various therapeutic areas, including central nervous system diseases, pain disorders, cancer, insomnia, anxiety and more.
This renewed scientific interest in the medical use of cannabinoids and CBD follows the recent discovery of the endocannabinoid system in humans.
The endocannabinoid system is a widespread and complex cell-signalling system that regulates multiple functions, including cognition, sleep, mood, inflammation and pain, and is activated via the CB1 and CB2 receptors in the brain and body, respectively.
CBD has already been used for hundreds of years to treat ailments – it’s not a new molecule or ingredient – however, it hasn’t been validated clinically or developed as a therapeutic drug at this point, and that needs to change.
While many patients and medical professionals know CBD has potential benefits, medical professionals cannot prescribe it to their patients without clinical validation. Acknowledging the critical opportunities and gaps in cannabinoid research and data, Vancouver-based Brains Bioceutical has provided evidence to support the efficacy and safety of phyto-cannabinoids in treating major diseases, and has partnered with numerous companies and research institutions, conducting pre-clinical research and clinical trials in various jurisdictions.
Brains Bio, through its wholly-owned subsidiary BSPG Laboratories, produces a natural, non-GMO, hemp-sourced CBD active pharmaceutical ingredient (API) with a purity greater than 99%. It has 0% THC or other prohibited substances and no pesticides, herbicides, heavy metals or radioactivity. This CBD API has been tested by a World Anti-Doping Agency (WADA) lab, NSF and Informed Choice and confirmed for the absence of THC and banned substances.
Brains Bio is involved in 15 clinical trials using CPD API, exploring its effects on treating COVID-19, epilepsy, anxiety, insomnia, opioid addiction and muscle inflammation. Once the results of the clinical trials are available, we will have the research and empirical data needed to solidify our leadership and expertise in using phyto-cannabinoids to treat major diseases and improve patient outcomes.
The team at Brains Bio brings decades of experience in pharmaceuticals, biotechnology and phyto-cannabinoids. This includes in-depth knowledge of capital markets, research and development, clinical trials, product development and the highly complex regulatory landscape governing cannabinoid production worldwide.
Brains Bioceutical has come into the market to ensure the right product is available to the right researchers. As the medical community becomes more educated on CBD use, I’m confident CBD will continue to blaze a trail to more sustainable and effective treatment. ç
Barinder Bhullar is senior vice-president, corporate affairs, at Brains Bioceutical.
